Long-term studies show sustained safety, though most research covers acute to subacute periods (weeks to months)
People who are recovering from tendon, ligament, or muscle injuries, with persistent gut disorders (IBD, ulcers, leaky gut), inflammation or tissue damage from NSAIDs, wanting speedier surgery or injury recovery, managing brain-gut dysfunction or systemic inflammation.
The reality check: longer trials did not justify a commercial obesity drug The same obesity-pharmacotherapy review literature notes that development was terminated after a longer trial failed to demonstrate sufficiently meaningful weight loss to be commercially viable
Oral supplementation (50150 g daily) may suit dietary deficiency without nerve involvement, but malabsorption cases require injections
They are well-known to doctors and patients
Sequences that could not be definitively assigned to a phylum were labeled unclassified (Fig